ReviewAdvances in experimental medicine and biology2021
CXCL11 Signaling in the Tumor Microenvironment.
Review in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Circulating cytokines levels and the risk of polycystic ovary syndrome: A Mendelian randomization analysis.Medicine · 2025Pooled it
- Shared Biomarkers LCN2 and CXCL11 for Ulcerative Colitis and Colon Cancer: Bioinformatics Analysis and Diagnostic Model Construction.Digestive diseases and sciences · 2026Article
- The causal relationship in hypertensive encephalopathy: mechanistic analysis of five specific circulating cytokines.Open medicine (Warsaw, Poland) · 2026Article
- Inflammatory Proteins Mediate the Causal Association between Sleep Traits and Breast Cancer: A Mendelian Randomization Study.Lifestyle genomics · 2026Article
- Personalized CRISPR knock-in cytokine gene therapy to remodel the tumor microenvironment and enhance CAR T cell therapy in solid tumors.Nature communications · 2025Article
- ATRA upregulates OTUD6B to recruit CD8Cell death & disease · 2025Article
- The RNA-Binding Proteins MCPIP2 and IGF2BP1 Competitively Modulate Breast Tumor Angiogenesis by Antagonizing VEGFA mRNA Stability and Expression.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- The role of CXC chemokines and receptors in breast cancer.Clinical and experimental medicine · 2025Review
- Integrated omics characterization reveals reduced cancer indicators and elevated inflammatory factors after thermal ablation in non-small cell lung cancer patients.Respiratory research · 2024Article
- A count-based model for delineating cell-cell interactions in spatial transcriptomics data.Bioinformatics (Oxford, England) · 2024Article
- Analyzing the Functional Roles and Immunological Features of Chemokines in COAD.International journal of molecular sciences · 2024Article
- Review
- Stem-like signatures in human meningioma cells are under the control of CXCL11/CXCL12 chemokine activity.Neuro-oncology · 2023Article
- Targeting CXCL9/10/11-CXCR3 axis: an important component of tumor-promoting and antitumor immunity.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Review
- Inhibition of IDH3α Enhanced the Efficacy of Chemoimmunotherapy by Regulating Acidic Tumor Microenvironments.Cancers · 2023Article
- Article
- CXCR3 predicts the prognosis of endometrial adenocarcinoma.BMC medical genomics · 2023Article
- An artificial intelligence prediction model based on extracellular matrix proteins for the prognostic prediction and immunotherapeutic evaluation of ovarian serous adenocarcinoma.Frontiers in molecular biosciences · 2023Article
- Article
- Histopathologic and transcriptomic phenotypes of a conditional RANKL transgenic mouse thymus.Cytokine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CXCL11 which can bind to two different chemokine receptors, CXCR3 and CXCR7, has found a prominent place in current tumor research. In this chapter, we mainly discuss the current evidence on the role of the immune response of CXCL11 in tumor microenvironment (TME). The diverse functions of CXCL11 include inhibiting angiogenesis, affecting the proliferation of different cell types, playing a role in fibroblast directed carcinoma invasion, increasing adhesion properties, suppressing M2 macrophage polarization, and facilitating the migration of certain immune cells. In addition, we discussed the application of CXCL11 as an adjuvant to various mainstream anti-cancer therapies and the future challenges in the application of CXCL11 targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.